covid-19

The pill hasn’t been approved by the Food and Drug Administration, but President Biden wants to be prepared if the drug receives federal signoff.

The government agreed to buy more doses of an antibody drug for the early treatment of Covid-19 developed by GlaxoSmithKline and Vir Biotechnology, bringing its total order to nearly $1 billion.

Testing found Pfizer’s pill to be 89% effective at reducing the risk of hospitalization and death from Covid-19 when taken soon after diagnosis.

The manufacturing agreement is the second by Medicines Patent Pool aiming to boost supplies of a pill to prevent Covid-19 infections from turning severe.

Represented by law firms with deep experience in insurance-coverage disputes, big companies are preparing for dragged-out legal fights.

The agreement requires the online retail giant to end practices that California’s attorney general said concealed Covid case counts.

KinderCare and Bright Horizons are among large child-care providers looking to expand their reach by buying up closed centers, with about 20% of the nation’s child-care facilities still closed since the pandemic’s onset.

The drugmaker said it would start pricing its Covid-19 vaccine to make it profitable, ending a period in which it had pledged to roll out the shots at cost during the pandemic.

Shots for children age 5 to 11 are one-third the size of doses for older people. Most pediatric and infectious-disease experts say parents shouldn’t delay.

Large trucking groups are fighting the federal rule in court while freight transport and warehousing firms say they encourage vaccinations but won’t demand them.

The application opens the door for authorization of the extra dose potentially before the end of the year, which could provide millions of people with another layer of security as winter drives many indoors.

Regeneron's Antibody Drug Cut Risk of Covid-19 by 82%, Company Says The data from a late-stage study suggest a potential use for the antibody drug as a prophylactic for the immunocompromised or others who aren’t well protected by vaccination. The data from a late-stage study suggest a potential...